AFAR's Mission

To support and advance Healthy Aging through Biomedical Research

Watch our Live Longer, Live Well video (right) to explore how a better world for older people is a better world for everyone.

Stay Connected

For updates on the impact of AFAR-supported research, upcoming events, news, and more, subscribe to our newsletter, EncourAGE.

Subscribe to EncourAGE Newsletter
Tablet Webinar

AFAR SuperAgers Initiative

95th Birthday Cake Crop

What's so Super
about SuperAgers?

Free Webinar
Wed May 29, 2024, 3pm ET

Super Agers Social Art Jan2024

SuperAgers Initiative

Learn more about the Research Study
Join the SuperAgers Community

AFAR's Grant Programs

42

Years

4400

Talented Investigators

$

200

Million Funded

Green Spotlight Microscope

Investing in Talent

Novel Interventions

Believing in Innovation

AFAR News

AFAR News
Ask the Expert Interview: Economist and author Andrew J. Scott, MSc, DPhil, on The Longevity Imperative
AFAR News
AFAR Grantee in the News: Pinchas Cohen, MD, elected as a 2024 Fellow of the American Association for the Advancement of Science
News Item Logo Template NPR
AFAR Initiative in the News: NPR spotlights TAME Trial and AFAR Scientific Leadership
News Item Logo Template Hevo AFAR Whitebox
Announcing the Second Cohort of the Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research
New York Times News Item Logo Template
AFAR Experts in the News: Andrew Dillin, PhD, and Matt Kaeberlein, PhD, on “Why Do We Age?” in The New York Times
Prevention news
AFAR Live Better Longer column launches with Prevention: Debut Article Spotlights SuperAgers Family Study

AFAR's Leadership

AFAR provides infrastructure support and leadership for three initiatives funded by the National Institute on Aging (NIA).

NSC Whitebox

Providing leadership in the pursuit of basic research into the biology of aging

RCCN White Box

Catalyzing cross-disciplinary research across the NIA center programs

Clin STAR White Box

A national platform to advance transdisciplinary aging research

The TAME Trial

The AFAR-managed TAME (Targeting Aging with Metformin) Trial will establish a proof-of-concept that aging processes can be treated, just as we treat diseases.

The TAME Trial ultimately seeks the FDA to make aging an "indication" for treatment.

If aging is made an indication, the TAME Trial will mark a paradigm shift: from treating each age-related medical condition separately, to treating these conditions together, by targeting aging per se.

Learn about the TAME Trial
Public statements by individual AFAR employees, affiliates, or Board members do not imply endorsement by AFAR. AFAR’s viewpoints are expressed only through official releases after approval by its Executive Director or Board of Directors.

AFAR is grateful for the collaboration and support of our program partners, including:

Gilbert Foundation logo 2024 Green
Glenn White Box


David Gore

Hevolution whitebox
Mc Knight Whitebox
Sagol Whitebox

AFAR is proud to consistently receive the highest ratings from respected charity evaluators

CharityNavigator4StarBadge.png
Guidestar Sealof Transparency